Abstract:Objective To assess the value of 18F-fluorodeoxyglucose (FDG) coincidence SPECT in unknown primary tumors (UPT). Methods A retrospective analysis of 36 patients referred to 18F-FDG coincidence SPECT imaging for metastases from UPT was performed. Metastases were located in bone (n=19), lymph node (n=11), pleura (n=4) and liver (n=2). All of the 36 patients took conventional imaging diagnostic work-up within 4 weeks after 18F-FDG coincidence SPECT. Results Fifteen (42%) primary tumors were found by 18F-FDG coincidence SPECT and were verified by histopathology (n=6) or conventional imaging procedures and clinical follow-up (n=9). The sensitivity of 18F-FDG coincidence SPECT for detecting primary tumors was 42% (15/36). Among the 15 primary tumors identified by 18F-FDG coincidence SPECT, one was only detected by 18F-FDG; three were detected first by 18F-FDG, and then by conventional imaging methods, by oriented imaging; eleven were found by both 18F-FDG and conventional imaging modalities separately. 18F-FDG coincidence SPECT findings affected the therapeutic protocols of 14% (5/36) patients. 18F-FDG coincidence SPECT also identified additional previously unknown metastases in 53% (19/36) patients. Conclusion 18F-FDG coincidence SPECT is an effective method for primary tumor detection and for evaluation of tumor burden in UPT patients, and it is helpful for staging, selecting appropriate treatment protocols and predicting prognosis for these patients.

The Clinical Value of 18F-FDG Coincidence SPECT in Unknown Primary Tumors